Maruti Suzuki Sales Drop 46% To 86,830 Units In September 2021
Maruti Suzuki's total sales - including domestic sales, exports, and sales to other original equipment manufacturers (OEM) stood at 86,830 units in September 2021, compared to 160,442 units in the corresponding month last year, marking a sharp decline of 46 per cent year-on-year.
The country's largest carmaker, while reporting its sales figures for September, stated that the company's sales volume last month was adversely impacted due to shortage of electronic components. The company's sales dropped 34 per cent to 86,830 units month-on-month, compared to 1,30,699 units in August 2021.Â
Maruti Suzuki's sales of mini passenger vehicles, including models such as Alto, S-Presso in September 2021 stood at 14,936 units, compared to 27,246 units in the corresponding month last year, according to a regulatory filing by the company to the stock exchanges today.Â
The sales of compact passenger vehicles including models such as WagonR, Swift, Celerio, Ignis, Baleno, Dzire, Tour S, stood at 20,891 units last month, compared to 84,213 units in the corresponding month last year.
The company's total domestic sales - including passenger vehicles and light commercial vehicles stood at 66,415 units, compared to 150,040 units in the corresponding month last year. The total domestic passenger vehicles sold last month stood at 63,111 units, compared to 147,912 units in the same month last year.Â
On Friday, October 1, share price of Maruti Suzuki declined more than two per cent with the announcement of the auto sales figures for September. Shares of Maruti Suzuki were last trading 2.44 per cent lower at Rs 7,155.50 on the BSE.Â
Maruti Suzuki opened on the BSE today at Rs 7,230, inching to an intra day high of Rs 7,230, and an intra day low of Rs 7,093.50, in the trading session so far.Â
-
Getting To Work Costs Women More | The Reason Why
It is not just about women paying more than men. It is about women paying much more in cities than in villages.
-
AI Bias In Investing Cannot Be Eliminated, But It Can Be Governed
Framing is a particularly important example as identical financial information presented in terms of gains rather than losses can lead an LLM to reach a different assessment.
-
Joining The Dots | Dark Skies, Steady Diya: Why Hope Holds This Diwali
With war, a weak rupee and foreign outflows weighing on sentiment, policymakers at the NDTV World Summit and market veterans at NDTV Profit Ignite: Diwali Edition offered the same advice: stay invested and filter out the noise.
-
The Curious Case of Equitas Small Finance Bank And A CEO Who Quit For Stock
PN Vasudevan believes persistent investor concerns over a perceived conflict of interest had become a governance overhang on Equitas Small Finance Bank's stock, even as the lender improved profitability and asset quality.
-
Talking Points This Week: AI Cash Burn, A Tiger Comeback And An India That Still Finds Its Own Path
India is not immune to higher oil or tighter global liquidity, yet its earnings base is broader, its domestic policy levers are still available.
-
Foreign Investors Own Half Of HDFC Bank and ICICI Bank. An LTCG Cut Could Matter Most Here
Foreign portfolio investors have US$115 billion parked in HDFC Bank, ICICI Bank. If the government cuts long-term capital gains tax, Jefferies says returning foreign money could land here first.
-
'Never Seen This Level Of Negativity': Sandeep Tandon Says The Next Rally May Be Closer Than You Think
Veteran investor Sandeep Tandon says foreign selling is easing, large-caps are due a comeback and mid-caps are crowded, while he turns positive on gold, power and pharma this Diwali.
-
Indians Stay With Family, Not In Hotels | The Reason Why
India still lacks enough clean, reliable and affordable hotels for budget-conscious travellers.
-
The Economic Imperative: Analysing The Material Driving Force Behind India-Canada Strategic Reset
This economic complementarity is further reinforced by deep institutional investment ties and talent mobility, which form the bedrock of the bilateral framework.
-
Medicine Pricing: Where Must Profit Stop?
India must confront excessive margins, hidden incentives and regulatory gaps that threaten the integrity of medicine.